Artivion, Inc. AORT 深 滬
交易中 03-26 11:12:21 美东时间
36.55
+0.430
+1.19%
華盛通- 最 高36.93
- 今 開36.10
- 成交量 10.26万股
- 最 低 35.945
- 昨 收 36.12
- 總市值 17.50亿
- 52周最高 48.25
- 市盈率 靜 176.66
- 換手率 0.21%
- 52周最低 21.97
- 委 比 66.67%
- 總股本 4788.39万
- 歷史最高 48.25
- 量 比 1.07
- 振 幅 2.73%
- 歷史最低 3.82
- 每 手 1
- 風險率 7.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Canaccord Genuity Maintains Buy on Artivion, Lowers Price Target to $48
Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $51 to $48.
02-14 03:23
电话会总结 ｜ Artivion(AORT)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Artivion业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **第四季度业绩：** - 调整后总收入：1.183亿美元（排除意大利回款调整），同比增长18.5% - 调整后EBITDA：2,270万美元，同比增长约29%（从1,760万美元增至2,270万美元） - 调整后EBITDA利润率：19.2%，同比改善110个基点 - 毛利率：63%，与2024年第四季度持平 **全年业绩：** - 调整后总收入：4.436亿美元，同比增长13% - 调整后EBITDA：同比增长26% - 调整后EBITDA利润率：20.2%，同比改善
02-13 12:19
Artivion Q4 Adj. EPS $0.17 Beats $0.08 Estimate, Sales $115.992M Miss $116.418M Estimate
Artivion (NYSE:AORT) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.08 by 107.32 percent. The company reported quarterly sales of $115.992 million which missed the analyst
02-13 05:09
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
Preview: Inspire Medical Systems's Earnings
Inspire Medical Systems (NYSE:INSP) is set to give its latest quarterly earning...
02-11 03:02
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
The Analyst Verdict: Artivion In The Eyes Of 4 Experts
4 analysts have expressed a variety of opinions on Artivion (NYSE:AORT) over th...
02-03 06:00
Needham Reiterates Buy on Artivion, Maintains $58 Price Target
Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $58 price target.
02-03 01:59
Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials
Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeon
02-02 21:01
Alphatec is the top performing healthcare equipment stock YTD
The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell short of its May highs. The sector is the sixth-highest performing sector a...
2025-12-23 01:12
